Lung cancer patients get second chance with triple therapy combo
NCT ID NCT05401786
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether a combination of two immunotherapy drugs (ipilimumab and cemiplimab) plus targeted radiation can help people with advanced non-small cell lung cancer whose previous immunotherapy stopped working. The study enrolls 54 participants and aims to see if the treatment can shrink tumors or keep them stable for at least 6 months. The approach is based on earlier research suggesting these therapies work better together.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Ipilimumab, Cemiplimab, and Stereotactic Body Radiotherapy
What this could lead to
If it works, this could offer a new treatment option for people with advanced lung cancer whose current immunotherapy has stopped working.
What could go wrong
This is a small, early-phase trial with only 54 participants, so results may not apply to everyone. The combination also carries risks of immune-related side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Antoni van Leeuwenhoek - Netherlands Cancer Institute
Amsterdam, North Holland, 1066 CX, Netherlands